Zopiclone Impurity | 865061-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Zopiclone Impurity
• 英文别名: 7-hydroxy-7H-furo[3,4-b]pyrazin-5-one
• CAS: 865061-50-3
• 化学式: C₆H₄N₂O₃
• 分子量: 152.11
• InChiKey: AQYCSXUTZDUELA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Aldose reductase inhibitors and uses thereof
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US10639306B2

  公开（公告）日：2020-05-05

  The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.

  本发明涉及新型化合物及其药物组合物，以及用本发明化合物和组合物促进皮肤健康老化、治疗皮肤疾病、治疗心血管疾病、治疗肾脏疾病、治疗血管生成疾病（如癌症）、治疗组织损伤（如非心脏组织损伤）、治疗不断发展的心肌梗塞以及治疗各种其他疾病（如糖尿病引起的并发症）的方法。其他疾病包括但不限于动脉粥样硬化、冠状动脉疾病、糖尿病肾病、糖尿病神经病变、糖尿病视网膜病变、皮肤感染、外周血管疾病、中风等。
• ALDOSE REDUCTASE INHIBITORS AND USES THEREOF
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20190201400A1

  公开（公告）日：2019-07-04

  The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.